# Arbutus Biopharma Corp (ABUS) — tender_offer/third_party [announced]
Source: SEC API (secapi.ai) · situation sit_aea01673d5a2cf697fb7 · retrieved 2026-08-14T08:09:12.007Z

## Overview
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, currently developing imdusiran (AB-729) for chronic hepatitis B treatment and an oral PD-L1 inhibitor (AB-101), while supporting its exclusive licensee Genevant in defending patented lipid nanoparticle technology.

Arbutus Biopharma announced plans to return capital to shareholders commencing in Q3 2026 through repurchases of up to approximately $230 million of the company's common shares. The repurchases may take the form of a tender offer (including a modified Dutch Auction tender offer), open market purchases, accelerated share repurchases, or other means. The specific form and timing remain subject to board approval, with no assurance that any repurchase activity will occur in Q3 2026 or at all.

## Terms
- Deal value: $230.0M · Consideration: cash

## Key dates
- Announced 2026-08-12

## Timeline
- 2026-08-12 · 8-K (0001171843-26-005442): 8-K - Arbutus Biopharma Corp — *Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, currently developing imdusiran (AB-729) for chronic hepatitis B treatment and an oral PD-L1 inhibitor (AB-101), while supporting its exclusive licensee Genevant in defending patented lipid nanoparticle technology.* Arbutus Biopharma announced plans to return capital to shareholders commencing in Q3 2026 through repurchases of up to approximately $230 million of the company's common shares. The repurchases may take the form of a tender offer (including a modified Dutch Auction tender offer), open market purchases, accelerated share repurchases, or other means. The specific form and timing remain subject to board approval, with no assurance that any repurchase activity will occur in Q3 2026 or at all.
  https://www.sec.gov/Archives/edgar/data/1447028/0001171843-26-005442.txt

## Citations
- 0001171843-26-005442 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000117184326005442